IGF1
IGF-1 is a growth-promoting peptide hormone that activates PI3K/AKT/mTOR signaling to drive anabolic processes. While essential for development, chronically elevated IGF-1 is associated with accelerated aging, and reduced IGF-1 signaling consistently extends lifespan in model organisms.
Key Takeaways
- •IGF-1 is the primary mediator of growth hormone’s anabolic effects, regulating cell growth and survival.
- •Lower IGF-1 signaling is consistently linked to extended lifespan and cancer protection in model organisms and humans.
- •Circulating IGF-1 levels are highly sensitive to dietary protein intake, especially methionine and leucine.
- •Optimal longevity appears to be associated with moderate, stable IGF-1 levels—avoiding both extremes.
Basic Information
- Gene Symbol
- IGF1
- Full Name
- Insulin-like Growth Factor 1
- Also Known As
- Somatomedin CIGF-I
- Location
- 12q23.2
- Protein Type
- Peptide Hormone
- Protein Family
- Insulin-like growth factor
Related Isoforms
The primary receptor for IGF-1 signaling
Binding proteins that regulate IGF-1 bioavailability
Key SNPs
Polymorphism associated with circulating IGF-1 levels and cancer risk; the C allele is linked to higher levels.
Associated with circulating IGF-1 levels and susceptibility to breast and colorectal cancer.
Influences mRNA stability; associated with circulating IGF-1 levels across multiple GWAS studies.
Associated with serum IGF-1 concentration and risk of type 2 diabetes and metabolic traits.
Located in the promoter region; linked to differential IGF-1 expression and cancer susceptibility.
Identified in large-scale GWAS as a significant locus for IGF-1 level variation.
Associated with various cancers and potentially protective against high myopia.
Overview
IGF-1 (Insulin-like Growth Factor 1) is a 70-amino acid peptide hormone produced primarily in the liver. It is the effector molecule of Growth Hormone (GH), mediating its anabolic effects throughout the body. Structurally similar to insulin, IGF-1 occupies a central role in the nutrient-sensing network that governs the trade-off between growth and longevity.
In the somatotropic axis, the pituitary releases GH, which stimulates the liver to produce IGF-1. Once in the blood, IGF-1 circulates mostly bound to IGFBPs, with IGFBP-3 being the most abundant. Free IGF-1 binds to the IGF-1 receptor (IGF1R), triggering intracellular cascades that promote cell division, inhibit cell death, and stimulate protein synthesis.
Conceptual Model
A simplified mental model for the pathway:
IGF-1 acts as the bridge between systemic signals (GH, nutrition) and cellular growth programs.
Core Health Impacts
- • Developmental Growth: Promotes skeletal and muscular growth during development
- • Tissue Maintenance: Maintains muscle mass and bone density in adults
- • Neuroprotection: Protects neurons from apoptosis (neurotrophic effect)
- • Renal Function: Regulates renal blood flow and glomerular filtration rate
- • Cancer Risk: High levels increase risk of breast, prostate, and colon cancers
- • Cardiovascular Health: Low levels are associated with cardiovascular disease and frailty
Protein Domains
B & A Domains
Highly homologous to the B and A chains of insulin; contains the three critical disulfide bridges that maintain the fold.
C Domain
A 12-residue linker that is not cleaved (unlike insulin), required for high-affinity binding to the IGF-1 receptor.
D Domain
An 8-residue C-terminal extension unique to IGFs, influencing receptor specificity and binding protein interactions.
Upstream Regulators
Growth Hormone (GH) Activator
The primary endocrine driver; GH binds to GHR in the liver to stimulate IGF1 transcription.
Dietary Protein Activator
Essential amino acids (especially methionine and leucine) stimulate hepatic IGF-1 production via nutrient sensing.
Insulin Activator
Enhances GH receptor sensitivity and suppresses IGFBP-1, increasing bioactive free IGF-1.
LKB1-AMPKα1 Pathway Activator
Regulates IGF-1 secretion in hepatocytes, linking cellular energy status to systemic growth signaling.
Estrogens Activator
Modulate the GH–IGF-1 axis; oral estrogen can decrease IGF-1 while transdermal estrogen may increase it.
Thyroxine (T4) Activator
Permissive effect on GH action and IGF-1 production; essential for normal skeletal growth.
Downstream Targets
IGF1 Receptor (IGF1R) Activates
Primary mediator of IGF1 effects; a tyrosine kinase receptor that activates PI3K and MAPK pathways.
PI3K–AKT–mTOR Pathway Activates
Drives protein synthesis, cell growth, and survival; inhibited by low IGF-1 signaling.
Ras–MAPK–ERK Pathway Activates
Promotes cellular proliferation and gene expression changes associated with growth.
FOXO transcription factors Inhibits
Inhibited by IGF1-driven AKT phosphorylation, reducing stress-resistance and autophagy.
GSK3β Inhibits
Inhibited by IGF1 signaling, promoting glycogen synthesis and cell cycle progression.
JAK–STAT3 Pathway Activates
Activated by IGF1R to regulate specific gene programs involved in cell transformation and survival.
Role in Aging
The Insulin/IGF-1 signaling (IIS) pathway is the most evolutionarily conserved aging pathway. Genetic reduction of IGF-1 signaling extends lifespan in worms, flies, and mice. In humans, the relationship is more nuanced but generally favors lower signaling for longevity.
Proteostasis Maintenance
High IGF-1 signaling inhibits autophagy via mTORC1 and FOXO suppression. Lowering IGF-1 allows for better clearance of damaged proteins and organelles.
Stress Resistance
Reduced IGF-1 signaling leads to nuclear translocation of FOXO, which upregulates antioxidant enzymes (SOD2, catalase) and DNA repair genes.
Cancer Protection
High IGF-1 is a potent mitogen. Lower levels reduce the proliferative drive of pre-cancerous cells, a key longevity mechanism in humans.
Stem Cell Exhaustion
Excessive IGF-1 can drive rapid stem cell proliferation, leading to earlier exhaustion. Balanced signaling preserves the regenerative pool.
Metabolic Flexibility
Reduced IGF-1 signaling often coincides with improved insulin sensitivity and lower fasting glucose, markers of a "younger" metabolic profile.
Human Centenarian Link
Many studies find that centenarians and their offspring have lower circulating IGF-1 or variants that reduce IGF-1 receptor activity.
Disorders & Diseases
Laron Syndrome (GH Insensitivity)
Caused by mutations in the GHR gene, resulting in extremely low IGF-1 levels. Characterized by short stature but near-total protection from cancer and diabetes.
Acromegaly & Gigantism
Result from GH-secreting pituitary adenomas. Excessive IGF-1 causes overgrowth of bone and soft tissue, cardiomegaly, and significantly increased cancer risk.
Cancer Susceptibility
Epidemiological studies consistently link high-normal IGF-1 levels to increased risks of breast, prostate, and colorectal cancers due to its pro-proliferative and anti-apoptotic effects.
Adult IGF-1 Deficiency
Can occur due to pituitary damage or aging (somatopause). Associated with reduced muscle mass, increased adiposity, osteoporosis, and impaired cognitive function.
Cardiovascular Disease
A "U-shaped" relationship exists: both excessively high and excessively low IGF-1 are risk factors. Adequate IGF-1 is needed for endothelial health and cardiac repair.
Interventions
Supplements
Essential cofactor for IGF-1 synthesis; deficiency is linked to reduced circulating IGF-1 levels.
Positively correlates with IGF-1; supplementation can increase IGF-1 in deficient individuals.
Supports the GH–IGF-1 axis; magnesium status is often positively associated with IGF-1 bioactivity.
Amino acids that can acutely stimulate GH secretion, potentially raising downstream IGF-1.
May increase local IGF-1 (MGF) expression in muscle tissue, supporting hypertrophy.
Lifestyle
Reducing animal protein (methionine) intake is the most potent dietary way to lower circulating IGF-1.
Reduces IGF-1 levels and improves insulin sensitivity, a hallmark of longevity-promoting diets.
Fasting beyond 48–72 hours triggers a dramatic drop in IGF-1 and a rise in IGFBP-1.
Acutely increases local muscle IGF-1 (MGF) for repair while improving long-term GH sensitivity.
Deep sleep is when the largest pulses of GH occur, which drives next-day IGF-1 production.
Medicines
Recombinant human IGF-1 used to treat severe primary IGF-1 deficiency (Laron syndrome).
Somatostatin analogs that inhibit GH secretion, used to lower IGF-1 in acromegaly.
GH receptor antagonist that blocks hepatic IGF-1 production; used for refractory acromegaly.
Reduces hyperinsulinemia and may indirectly lower bioactive IGF-1 levels.
Selective estrogen receptor modulator that can significantly lower circulating IGF-1 levels.
Lab Tests & Biomarkers
Standard Labs
The primary clinical test; must be interpreted using age- and sex-specific reference ranges.
The main binding protein; often measured to calculate the IGF-1/IGFBP-3 ratio (a proxy for bioactivity).
Used when GH deficiency is suspected; measures the pituitary’s ability to release GH.
Specialized Tests
Measures the unbound, biologically active fraction; more sensitive but less standardized than total IGF-1.
Part of the ternary complex that carries IGF-1; deficiency can cause low IGF-1 levels.
A markers of acute metabolic status; increases with fasting and lowers with insulin.
Genetic & Indirect
Used to diagnose Laron syndrome and other forms of GH insensitivity.
SNPs in the receptor can influence sensitivity to circulating IGF-1.
Since insulin drives free IGF-1, insulin resistance is a key variable in IGF-1 biology.
Hormonal Interactions
Growth Hormone Primary Driver
Secreted by the pituitary; stimulates hepatic IGF-1 production as the effector of the somatotropic axis.
Insulin Synergist
Shares structural similarity; high insulin increases free IGF-1 by suppressing its binding proteins.
Testosterone Anabolic Partner
Works alongside IGF-1 to promote muscle protein synthesis and bone density.
Estrogen Complex Regulator
Oral estrogens decrease IGF-1 via first-pass liver effects; transdermal may support levels.
Cortisol Antagonist
High cortisol impairs GH secretion and can induce IGF-1 resistance in peripheral tissues.
Somatostatin Inhibitor
Pituitary hormone that blocks GH release, effectively shutting down the upstream drive for IGF-1.
Deep Dive
Network Diagrams
The GH–IGF-1 Somatotropic Axis
IGF-1 Cellular Signaling Network
The GH–IGF-1 Axis: Systemic Coordination of Growth
IGF-1 signaling is not just a cellular event but a tightly regulated systemic feedback loop known as the Somatotropic Axis. Regulation occurs at every level from the brain to the cell membrane.
The Pituitary Drive: Growth Hormone is released in pulses, primarily during deep sleep and in response to exercise or fasting. GH travels to the liver, where it binds to GH receptors, activating the JAK-STAT pathway to drive the transcription of the IGF1 gene.
Bioavailability Gating: 99% of IGF-1 in the blood is bound to proteins. The most important is the ternary complex consisting of IGF-1, IGFBP-3, and ALS. This complex extends the half-life of IGF-1 from minutes to over 12 hours, acting as a reservoir of growth potential.
Receptor Dynamics: Free IGF-1 binds to the IGF1R, a pre-formed dimer. Binding triggers autophosphorylation of the kinase domain, creating docking sites for IRS1/2 adaptors. This bridge then activates the PI3K-AKT and MAPK cascades that execute the growth program.
The Longevity Paradox: Growth vs. Maintenance
Why would a hormone essential for life and muscle be “pro-aging”? The answer lies in the Disposable Soma Theory: organisms must choose between investing energy in reproduction/growth or in long-term maintenance/repair.
Hyper-growth as a driver of damage: High IGF-1 keeps the cellular engine in high gear. This increases metabolic byproducts, suppresses autophagy (cellular cleanup), and drives “hyper-function”—a state where cells operate at a level that eventually leads to exhaustion and senescence.
The IGF-1/Insulin Overlap: Because IGF-1 can bind to insulin receptors and vice-versa (at high concentrations), these pathways are deeply intertwined. Chronic hyperinsulinemia effectively “amplifies” the growth signal of IGF-1, making high-sugar/high-protein diets a double-hit for accelerated aging.
U-Shaped Mortality: In older age, very low IGF-1 becomes a liability, leading to frailty and immune decline. The goal for longevity is not zero IGF-1, but a moderate and sensitive axis that can respond to needs without being chronically overdriven.
Signal Transduction and Feedback
Once the IGF1R is activated, it recruits a network of proteins that coordinate different aspects of cell physiology.
The PI3K-AKT Branch: Primarily responsible for the metabolic and survival effects. AKT inhibits FOXO (nuclear exclusion) and activates mTORC1, shifting the cell into an anabolic state.
The MAPK Branch: Primarily responsible for the mitogenic effects (cell division). This branch is often the one hijacked in cancer cells to drive uncontrolled growth.
Negative Feedback: Just as IGF-1 provides feedback to the pituitary to stop GH release, intracellular proteins like S6K (downstream of mTOR) can inhibit IRS1, providing a “brake” on continued signaling. Loss of these brakes is a common feature of metabolic disease.
Practical Notes for Interpreting Lab Results
Total vs. Free IGF-1: A "normal" total IGF-1 can still hide high bioactivity if binding proteins (IGFBP-3) are low. Conversely, high insulin can lower IGFBP-1, raising free IGF-1 even if total levels look fine.
The "Youthful" Range: While doctors use a broad reference range, many longevity practitioners aim for the 25th–50th percentile of the age-matched range to maximize the balance between cancer protection and muscle maintenance.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Summarizes how reduced GH/IGF-1 signaling is the most robustly associated pathway with extended longevity across species.
The landmark study of Laron syndrome individuals in Ecuador showing near-immunity to cancer and diabetes.
Identified that both very low and very high IGF-1 levels are associated with increased mortality in a large human cohort.
Mendelian randomization study confirming a causal link between higher IGF-1 and risks of breast, prostate, and colorectal cancer.
Demonstrated that offspring of centenarians have lower IGF-1 bioactivity than age-matched controls.
Showed that protein restriction reduces IGF-1 levels and inhibits cancer progression in human and animal models.